retatrutide efficacy clinical trials A new trial from Eli Lilly and Company suggests its experimental triple hormone drug, retatrutide, could become one of the next major medications in the rapidly growing weight loss and diabetes Eli Lilly infiltrates anti-obesity market

Here are some key benefits of GLP-1 patches: Convenience: No need for daily injections, making it easier to adhere to treatment plans

While restaurants in the region have not widely branded offerings as 'Ozempic menus,' hospitality experts expect more customised smaller-portion options as demand grows

In March of this year, Wegovy was approved for overweight or obese patients with cardiovascular disease

PMID: 38302593 | doi:10.1038/s41366-024-01473-y Sanyal AJ et al

doi: 10.1016/j.bbrc.2015.09.179 40 HuangMWeiRWangYSuTLiQYangXet al

The most common side effects of GLP-1 drugs are gastrointestinal and mild, particularly when starting treatment